Changes to the Code
H.R. 1051 · To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 355 New drugs
4 changes the bill asks for here, 4 carried out
- Carried out:
by inserting
and subclause (III)
aftersubparagraph (D)
; and - Carried out:
by inserting before the period at the end the following:
or an applicant whose application was approved pursuant to subclause (III). If an applicant described in subclause (III) is eligible for effective approval on the same day a tentatively approved first applicant who has requested final approval is determined by the Secretary to be eligible for effective approval by meeting all the approval requirements of this subsection, such applicant may not receive effective approval until 180 days after the first applicant begins commercial marketing of the drug
; and - Carried out:
by adding at the end the following new subclause:
(III) Applicant approval.— The Secretary may approve an application containing a certification described in paragraph (2)(A)(vii)(IV) that is for a drug for which a first applicant has submitted an application containing such a certification, notwithstanding the eligibility of a …
- Carried out:
Section 505(j)(5)(D) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355 (j)(5)(D)) is amended by adding at the end the following:
(v) Special forfeiture rule for certain subsequent applicants.— (I) In general.— Except as specified in subclause (II), an application that is approved pursuant to subclause (III) of subparagraph (B)(iv) is deemed to be tentatively approved and to no longer have an effective …
§ 355(j)(5)(B)The approval of an application submitted under paragraph (2) shall be made…(iii)–(iv)
Start of § 355 to (j)(5)(B)(iii)(IV) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (iii) | In such an action, each of the parties shall reasonably cooperate in expediting the action. | In such an action, each of the parties shall reasonably cooperate in expediting the action. | ||
| (iv) | (iv) 180-day exclusivity period.— | (iv) 180-day exclusivity period.— | ||
| (iv)(I) | (I) Effectiveness of application.— | (I) Effectiveness of application.— | ||
| Subject to subparagraph (D), if the application contains a certification described in paragraph (2)(A)(vii)(IV) and is for a drug for which a first applicant has submitted an application containing such a certification, the application shall be made effective on the date that is 180 days after the date of the first commercial marketing of the drug (including the commercial marketing of the listed drug) by any first applicant. | Subject to subparagraph (D)[inserted: and subclause (III)], if the application contains a certification described in paragraph (2)(A)(vii)(IV) and is for a drug for which a first applicant has submitted an application containing such a certification, the application shall be made effective on the date that is 180 days after the date of the first commercial marketing of the drug (including the commercial marketing of the listed drug) by any first applicant[inserted: or an applicant whose application was approved pursuant to subclause (III)].[inserted: If an applicant described in subclause (III) is eligible for effective approval on the same day a tentatively approved first applicant who has requested final approval is determined by the Secretary to be eligible for effective approval by meeting all the approval requirements of this subsection, such applicant may not receive effective approval until 180 days after the first applicant begins commercial marketing of the drug.] | |||
| (iv)(II) | (II) Definitions.— | (II) Definitions.— | ||
| In this paragraph: | In this paragraph: | |||
| (iv)(II)(aa) | (aa) 180-day exclusivity period.— | (aa) 180-day exclusivity period.— | ||
| The term “180-day exclusivity period” means the 180-day period ending on the day before the date on which an application submitted by an applicant other than a first applicant could become effective under this clause. | The term “180-day exclusivity period” means the 180-day period ending on the day before the date on which an application submitted by an applicant other than a first applicant could become effective under this clause. |
§ 355(j)(5)(B)The approval of an application submitted under paragraph (2) shall be made…(iv)–(v)
(j)(5)(B)(iv)(II)(bb)–(dd) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (iv)(II)(dd)(AA) | (AA) In general.— | (AA) In general.— | ||
| The term “tentative approval” means notification to an applicant by the Secretary that an application under this subsection meets the requirements of paragraph (2)(A), but cannot receive effective approval because the application does not meet the requirements of this subparagraph, there is a period of exclusivity for the listed drug under subparagraph (F) or section 355a of this title, or there is a 7-year period of exclusivity for the listed drug under section 360cc of this title. | The term “tentative approval” means notification to an applicant by the Secretary that an application under this subsection meets the requirements of paragraph (2)(A), but cannot receive effective approval because the application does not meet the requirements of this subparagraph, there is a period of exclusivity for the listed drug under subparagraph (F) or section 355a of this title, or there is a 7-year period of exclusivity for the listed drug under section 360cc of this title. | |||
| (iv)(II)(dd)(BB) | (BB) Limitation.— | (BB) Limitation.— | ||
| A drug that is granted tentative approval by the Secretary is not an approved drug and shall not have an effective approval until the Secretary issues an approval after any necessary additional review of the application. | A drug that is granted tentative approval by the Secretary is not an approved drug and shall not have an effective approval until the Secretary issues an approval after any necessary additional review of the application. | |||
| (iv)(III) | (III) [inserted: Applicant approval.—] | |||
| [inserted: The Secretary may approve an application containing a certification described in paragraph (2)(A)(vii)(IV) that is for a drug for which a first applicant has submitted an application containing such a certification, notwithstanding the eligibility of a first applicant for the 180-day exclusivity period described in subclause (II)(aa), if each of the following conditions is met:] | ||||
| (iv)(III)(aa) | (aa) [inserted: ] | |||
| [inserted: The approval of such application could be made effective, but for the eligibility of a first applicant for 180-day exclusivity under this clause.] | ||||
| (iv)(III)(bb) | (bb) [inserted: ] | |||
| [inserted: The applicant of such application has submitted a certification to the abbreviated new drug application that there are no conditions that would prevent the applicant from commercial marketing within 75 days after the date of approval and that the applicant intends to so market the drug.] | ||||
| (iv)(III)(cc) | (cc) [inserted: ] | |||
| [inserted: At least 33 months have passed since the date of submission of an application for the drug by at least one first applicant.] | ||||
| (iv)(III)(dd) | (dd) [inserted: ] | |||
| [inserted: Approval of an application for the drug submitted by at least one first applicant is not precluded under clause (iii).] | ||||
| (iv)(III)(ee) | (ee) [inserted: ] | |||
| [inserted: No application for the drug submitted by any first applicant is effectively approved on the date that the conditions under items (aa), (bb), (cc), and (dd) are all met and maintained.] | ||||
| (v) | (v) 180-day exclusivity period for competitive generic therapies.— | (v) 180-day exclusivity period for competitive generic therapies.— | ||
| (v)(I) | (I) Effectiveness of application.— | (I) Effectiveness of application.— | ||
| Subject to subparagraph (D)(iv), if the application is for a drug that is the same as a competitive generic therapy for which any first approved applicant has commenced commercial marketing, the application shall be made effective on the date that is 180 days after the date of the first commercial marketing of the competitive generic therapy (including the commercial marketing of the listed drug) by any first approved applicant. | Subject to subparagraph (D)(iv), if the application is for a drug that is the same as a competitive generic therapy for which any first approved applicant has commenced commercial marketing, the application shall be made effective on the date that is 180 days after the date of the first commercial marketing of the competitive generic therapy (including the commercial marketing of the listed drug) by any first approved applicant. | |||
§ 355(j)(5)(D)–(F)
(j)(5)(B)(v)(II)–(D)(iii)(I) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (D)(iii)(II) | (II) | (II) | ||
| no applicant shall be eligible for a 180-day exclusivity period. | no applicant shall be eligible for a 180-day exclusivity period. | |||
| (D)(iv) | (iv) Special forfeiture rule for competitive generic therapy.— | (iv) Special forfeiture rule for competitive generic therapy.— | ||
| The 180-day exclusivity period described in subparagraph (B)(v) shall be forfeited by a first approved applicant if the applicant fails to market the competitive generic therapy within 75 days after the date on which the approval of the first approved applicant’s application for the competitive generic therapy is made effective. | The 180-day exclusivity period described in subparagraph (B)(v) shall be forfeited by a first approved applicant if the applicant fails to market the competitive generic therapy within 75 days after the date on which the approval of the first approved applicant’s application for the competitive generic therapy is made effective. | |||
| (D)(v) | (v) [inserted: Special forfeiture rule for certain subsequent applicants.—] | |||
| (D)(v)(I) | (I) [inserted: In general.—] | |||
| [inserted: Except as specified in subclause (II), an application that is approved pursuant to subclause (III) of subparagraph (B)(iv) is deemed to be tentatively approved and to no longer have an effective approval pursuant to such subclause (III) beginning on the day after the end of the 75-day period specified in item (bb) of such subclause (III) if the applicant fails to commence commercial marketing as required under such item.] | ||||
| (D)(v)(II) | (II) [inserted: Opportunity to cure.—] | |||
| (D)(v)(II)(aa) | (aa) [inserted: In general.—] | |||
| [inserted: If the applicant of an application approved pursuant to subclause (III) of subparagraph (B)(iv) submits, pursuant to item (bb) of such subclause, a notification that it can no longer commence commercial marketing within the 75-day period specified in such item, such application is deemed to be tentatively approved and to no longer be effectively approved beginning on the date that such a notification is received.] | ||||
| (D)(v)(II)(bb) | (bb) [inserted: Ineligibility for subsequent effective approval.—] | |||
| [inserted: If an applicant described in item (aa) does not commence commercial marketing within such 75-day period, the applicant shall not be eligible for a subsequent effective approval for the application involved under subclause (III) of subparagraph (B)(iv) unless, in addition to meeting each of the conditions in such subclause (III), the applicant submits a certification to its abbreviated new drug application that—] | ||||
| (D)(v)(II)(bb)(AA) | (AA) [inserted: ] | |||
| [inserted: an event that could not have been reasonably foreseen by the applicant prevented it from commencing commercial marketing; and] | ||||
| (D)(v)(II)(bb)(BB) | (BB) [inserted: ] | |||
| [inserted: it has fully resolved any issues preventing such commercial marketing from commencing as a result of such event.] | ||||
| (D)(v)(II)(cc) | (cc) [inserted: Timing for submission.—] | |||
| [inserted: An applicant described in item (aa) shall, not later than one business day after commencing marketing of the drug that is the subject of the application described in such item, submit a notification to the abbreviated new drug application confirming that such applicant has commenced commercial marketing of the drug.] | ||||
| (E) | (E) | (E) | ||
| If the Secretary decides to disapprove an application, the Secretary shall give the applicant notice of an opportunity for a hearing before the Secretary on the question of whether such application is approvable. If the applicant elects to accept the opportunity for hearing by written request within thirty days after such notice, such hearing shall commence not more than ninety days after the expiration of such thirty days unless the Secretary and the applicant otherwise agree. Any such hearing shall thereafter be conducted on an expedited basis and the Secretary’s order thereon shall be issued within ninety days after the date fixed by the Secretary for filing final briefs. | If the Secretary decides to disapprove an application, the Secretary shall give the applicant notice of an opportunity for a hearing before the Secretary on the question of whether such application is approvable. If the applicant elects to accept the opportunity for hearing by written request within thirty days after such notice, such hearing shall commence not more than ninety days after the expiration of such thirty days unless the Secretary and the applicant otherwise agree. Any such hearing shall thereafter be conducted on an expedited basis and the Secretary’s order thereon shall be issued within ninety days after the date fixed by the Secretary for filing final briefs. | |||
| (F) | (F) | (F) | ||
Rest of § 355 unchanged